Demant stock analysis
Want to see WILYY full AI Analyst Report?
Demant (WILYY) Stock Price & Analysis
WILYY Stock Chart & Stats
- Day’s Range
- $27.48 - $27.48
- 52-Week Range
- $13.80 - $28.31
- Previous Close
- $27.54
- Volume
- N/A
- Average Volume (3M)
- 160
- Market Cap
- $11.23B
- Enterprise Value
- $11.45B
- Total Cash (Recent Filing)
- $1.50B
- Total Debt (Recent Filing)
- $20.28B
- Price to Earnings (P/E)
- 48.0
- Beta
- 0.91
- Next Earnings
- Feb 09, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth
Strong organic growth alongside acquisitive expansion indicates continuing demand for Demant’s hearing-health portfolio. The upgraded outlook supports durable revenue momentum, while broader hearing-care exposure can reinforce growth across products, clinics, diagnostics, and services.
Product Innovation And Commercial Momentum
New premium products and demonstrated adoption of Oticon Zeal strengthen Demant’s competitive position in hearing aids. Innovation in speech clarity, connectivity, and feedback control can support premium positioning, customer retention, and share gains over coming quarters.
Strong Gross Profit Economics
Gross profit growth exceeding revenue growth and higher gross margin point to favorable product, channel, and geographic mix. These economics provide financial capacity to fund innovation and integration while supporting more resilient earnings as the portfolio expands.
Bears Say
Elevated Leverage
The more debt-heavy capital structure reduces financial flexibility and increases refinancing sensitivity if earnings weaken. Although leverage has improved from the post-acquisition spike, remaining above the target range may constrain investment and shareholder capital allocation.
Profitability Pressure
The gap between rapid revenue expansion and weaker operating and net margins indicates that growth is not yet translating proportionally into earnings. Persistent cost, mix, or operating-leverage pressure could limit cash accumulation and reduce the benefit of higher sales.
Higher Integration And Restructuring Costs
Rising special items show that acquisitions and restructuring require more cash and management attention than previously expected. These costs can dilute reported earnings, delay full synergy realization, and make near-term profitability more dependent on successful integration execution.
Demant News
WILYY FAQ
What was Demant’s price range in the past 12 months?
What is Demant’s market cap?
When is Demant’s upcoming earnings report date?
How were Demant’s earnings last quarter?
Is Demant overvalued?
Does Demant pay dividends?
What is Demant’s EPS estimate?
How many shares outstanding does Demant have?
What happened to Demant’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Demant?
What is the TipRanks Smart Score and how is it calculated?
Demant Stock Smart Score
Company Description
Demant
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Søren Nielsen
- Employees
- 26,704
- Website
- www.demant.com
- Address
- Kongebakken 9, Smørum, ZE, 2765, DK
Demant (WILYY) Earnings & Revenues
WILYY Company Deck
WILYY Earnings Call
Earnings Call SentimentPositive
The call presented multiple strong operational and financial positives: robust reported revenue growth (15%), gross profit expansion (+17%) and gross margin improvement (+1.1 ppt), solid cash generation, successful commercial momentum driven by Oticon Zeal and the new Oticon Reveal product positioning, and upgraded full-year guidance. Offsetting these positives are elevated and increased special items tied to acquisitions and restructurings, FX headwinds, regional softness (notably China and managed care in the U.S.), and the risk of competitive launches in H2. On balance, the company’s financial performance, product momentum, successful integration progress and strengthened outlook outweigh the headwinds and one-off costs.
View all WILYY earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 6 | 5 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 8 | 0 | 4 |













